Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Predicting the prognosis of glioma patients with TERT promoter mutations and guiding the specific immune profile of immune checkpoint blockade therapy.

Aging - 18 Mar 2024

Cao Wenpeng, Lan Jinzhi, Hu Chujiao, Kong Jinping, Xiang Limin, Zhang Zhixue, Sun Yating, Zeng Zhirui, Lei Shan

Abstract excerpt

The telomerase reverse transcriptase promoter (TERTp) is frequently mutated in gliomas. This study sought to identify immune biomarkers of gliomas with TERTp mutations. Data from TCGA were used to identify and validate survival-associated gene signatures, and immune and stromal scores were calculated using the ESTIMATE algorithm. High stromal or immune scores in patients with TERTp-mutant gliomas correlated with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Brain Neoplasms
Share to Glioma

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immune Checkpoint Inhibitors

Share to Mutation

Share to Prognosis

Share to Telomerase

Source

Open in PubMed Open full text

Identifiers

PMID: 38499392
DOI: 10.18632/aging.205668
PMCID: PMC11006486

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Predicting the prognosis of glioma patients with TERT promoter mutations and guiding the specific immune profile of immune checkpoint blockade therapy.PMID 38499392Read ↗

TERT Mutation Is Accompanied by Neutrophil Infiltration and Contributes to Poor Survival in Isocitrate Dehydrogenase Wild-Type GliomaSemantic proximity Read ↗

Classification based on mutations of TERT promoter and IDH characterizes subtypes in grade II/III gliomas.Semantic proximity Read ↗

Immune-related matrisomes are potential biomarkers to predict the prognosis and immune microenvironment of glioma patients through bioinformatics analysis and experimental verificationSemantic proximity Read ↗

TERT Immunohistochemistry as a Surrogate Marker for TERT Promoter Mutations in Infiltrating Gliomas.Semantic proximity Read ↗

Association of Telomerase Reverse Transcriptase Promoter Mutations with the Prognosis of Glioma Patients: a Meta-Analysis.Semantic proximity Read ↗

Paradoxical prognostic impact of TERT promoter mutations in gliomas depends on different histological and genetic backgrounds.Semantic proximity Read ↗

M2 TAM-related risk signature based on single-cell and bulk RNA sequencing to evaluate tumor immune microenvironment and predict prognosis in gliomaSemantic proximity Read ↗

Molecular subtypes and prognostic analysis of cytokine-related genes in gliomasSemantic proximity Read ↗

A TGF ‐β signaling‐related lncRNA signature for prediction of glioma prognosis, immune microenvironment, and immunotherapy responseSemantic proximity Read ↗

A specific immune signature for predicting the prognosis of glioma patients with IDH1-mutation and guiding immune checkpoint blockade therapy.Semantic proximity Read ↗

TERT mutations correlate with higher TMB value and unique tumor microenvironment and may be a potential biomarker for anti-CTLA4 treatment.Semantic proximity Read ↗

Updates in prognostic markers for gliomasSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.